INT76714

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 2.33
Pain Relevance 4.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Drd3) plasma membrane (Drd3) signal transducer activity (Drd3)
Anatomy Link Frequency
nucleus accumbens 1
shell 1
putamen 1
Drd3 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 39 100.00 Very High Very High Very High
Nucleus accumbens 8 99.96 Very High Very High Very High
agonist 6 99.80 Very High Very High Very High
dopamine receptor 31 99.24 Very High Very High Very High
opiate 2 99.20 Very High Very High Very High
Endep 8 98.52 Very High Very High Very High
fluoxetine 6 98.22 Very High Very High Very High
Enkephalin 2 97.76 Very High Very High Very High
cocaine 5 92.88 High High
Neurotransmitter 1 87.84 High High
Disease Link Frequency Relevance Heat
Restless Legs Syndrome 89 98.54 Very High Very High Very High
Watson Syndrome 84 98.28 Very High Very High Very High
Anxiety Disorder 2 97.64 Very High Very High Very High
Dyskinesias 8 96.28 Very High Very High Very High
Targeted Disruption 20 95.44 Very High Very High Very High
Alzheimer's Dementia 9 95.00 High High
Shock 8 84.28 Quite High
Anaemia 5 73.40 Quite High
Movement Disorders 9 58.00 Quite High
Cognitive Disorder 54 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Through network analysis an interaction between APP and the dopamine 3 receptor (DRD3) was idenified.
DRD3 Binding (interaction) of associated with dopamine
1) Confidence 0.37 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1434756 Disease Relevance 0.35 Pain Relevance 0.21
These potential interactions between neurofibromin and APP or DRD3 might lead to new ideas about how neurofibromin is involved in cellular signaling and synaptic plasticity.
DRD3 Binding (interactions) of
2) Confidence 0.37 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1434756 Disease Relevance 0.38 Pain Relevance 0.31
To assess the interaction of morphine and D3 receptor ligands during acquisition of CPP, we have used a particular procedure, in which the animals were given the choice between compartments associated with either morphine alone or the combination of morphine with the tested agent.
D3 receptor Binding (interaction) of
3) Confidence 0.33 Published 2004 Journal Psychopharmacology (Berl.) Section Body Doc Link 15095031 Disease Relevance 0 Pain Relevance 0
Through network analysis an interaction between APP and the dopamine 3 receptor (DRD3) was idenified.
dopamine 3 receptor Binding (interaction) of associated with dopamine
4) Confidence 0.29 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1434756 Disease Relevance 0.35 Pain Relevance 0.21
ECT for 10 days increased D3 receptor mRNA and binding in the shell of nucleus accumbens.
D3 receptor Binding (binding) of in shell associated with nucleus accumbens
5) Confidence 0.21 Published 2000 Journal Mol. Psychiatry Section Abstract Doc Link 10889548 Disease Relevance 0.08 Pain Relevance 0.90
D3 receptor mutants are hyperactive when assessed in an exploratory assay and display reduced anxiety-associated behavior in an elevated plus maze test.
D3 receptor Binding (hyperactive) of associated with anxiety disorder
6) Confidence 0.18 Published 1998 Journal Dev. Neurosci. Section Abstract Doc Link 9691193 Disease Relevance 0.27 Pain Relevance 0.76
In contrast, treatments for 21 days (with all drugs except fluoxetine) significantly increased D3 receptor mRNA expression in the shell of nucleus accumbens; D3 receptor binding was also significantly increased by amitriptyline or fluoxetine after a 42-day treatment.
D3 receptor Binding (binding) of in nucleus accumbens associated with nucleus accumbens, endep and fluoxetine
7) Confidence 0.14 Published 2000 Journal Mol. Psychiatry Section Abstract Doc Link 10889548 Disease Relevance 0.08 Pain Relevance 0.87
Total and subregional striatal analysis showed no difference in D-1, D-2 or D-3 receptor binding in the caudate and putamen between monkeys receiving high dose L-dopa treatment with marked dyskinesia and those without dyskinesia compared to untreated animals.
D-3 receptor Binding (binding) of in putamen associated with dyskinesias
8) Confidence 0.03 Published 2001 Journal J Neural Transm Section Abstract Doc Link 11716146 Disease Relevance 0.36 Pain Relevance 0.27
Ropinirole was the first FDA-approved pharmacological agent for moderate to severe primary RLS.72 Ropinirole is classified as a non-ergolide dopamine agonist, and has affinity for the D2 and D3 receptor subtypes, but minimal affinity for the D1 receptor subtype.
D3 receptor Binding (affinity) of associated with dopamine, agonist and restless legs syndrome
9) Confidence 0.01 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857615 Disease Relevance 0.47 Pain Relevance 0.55

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox